Published in Clin Breast Cancer on August 01, 2008
Trastuzumab in Treating Women With Primary Breast Cancer | NCT00045032
MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. PLoS One (2012) 1.17
Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. PLoS One (2013) 1.04
EPMA position paper in cancer: current overview and future perspectives. EPMA J (2015) 1.04
Transcriptional profiling of ErbB signalling in mammary luminal epithelial cells--interplay of ErbB and IGF1 signalling through IGFBP3 regulation. BMC Cancer (2010) 0.88
ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers. PLoS One (2012) 0.87
Essential medicines for breast cancer in low and middle income countries. BMC Cancer (2015) 0.81
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity. BMC Cancer (2011) 0.79
Adjuvant Systemic Therapy of Breast Cancer. Breast Care (Basel) (2011) 0.79
The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure. Exp Clin Cardiol (2009) 0.78
The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity. Cardiovasc Ultrasound (2015) 0.77
SIK2 Restricts Autophagic Flux To Support Triple-Negative Breast Cancer Survival. Mol Cell Biol (2016) 0.76